GLP-1/GIP Therapy for Obesity: A New Era in Weight Management

Why Weight Loss Was So Hard Before These Drugs

For decades the advice for obesity was the same — eat less, move more — and for decades most people regained what they lost. That was never a failure of willpower. The body defends its highest weight by lowering metabolism and raising hunger hormones, and it keeps doing so for years. GLP-1 and dual GLP-1/GIP therapy is the first medical treatment that works on those signals directly, and it is why 15 to 20 per cent weight loss is now realistic without surgery.

These are prescription medicines with real effects and real side effects, not a shortcut. Used properly — alongside protein, resistance training and monitoring — they are the biggest advance in obesity medicine in a generation.

How GLP-1 and GIP Actually Work

GLP-1 and GIP are incretin hormones your gut releases after a meal. The medications are engineered versions that last a week instead of minutes, and they act in four places at once:

• The brain. They reduce appetite and quieten the constant food chatter most patients describe as the hardest part of dieting.
• The stomach. Emptying slows, so meals feel satisfying for far longer and portions naturally fall.
• The pancreas. Insulin release improves when sugar is high and glucagon falls, which is why they also lower HbA1c.
• Metabolism. Adding GIP to GLP-1, as tirzepatide does, improves how fat tissue handles energy and gives a larger average weight loss.

Crucially, appetite reduction is a physiological effect, not a stimulant one. Patients usually describe it as simply feeling full — not wired, not jittery.

Who Is Suitable for Treatment

These medicines are for a defined clinical problem, not for cosmetic weight loss. Treatment is generally appropriate when:

• BMI is 27 or above with a weight-related condition — type 2 diabetes, prediabetes, hypertension, fatty liver, sleep apnoea, PCOS or dyslipidaemia
• BMI is 30 or above, with or without a related condition
• Structured diet and activity have been tried and weight has plateaued or returned

They are not used in pregnancy or breastfeeding, in a personal or family history of medullary thyroid cancer or MEN 2, in active pancreatitis, or in severe gastroparesis. In India, where the metabolic risk of excess weight begins at a lower BMI than in Europe, the thresholds are applied with waist circumference in mind rather than BMI alone.

What Results to Expect

Average results from the major trials, achieved alongside diet and activity support, are shown below. Individual response varies widely — some patients lose considerably more, and a minority respond poorly and should stop.

Swipe the table sideways to see all columns →

The benefits extend past the scale: blood pressure, cholesterol, HbA1c, fatty liver and sleep apnoea all improve, and in patients with established heart disease semaglutide has been shown to reduce cardiovascular events.

Side Effects and How They Are Managed

The Common Ones

Nausea, reduced appetite, constipation, loose stools, burping and occasional vomiting affect a large minority, mostly in the first weeks and after each dose increase. Almost all of it is manageable: smaller meals, less fat and fried food, adequate fluids, fibre for constipation, and a slower dose escalation. Doses are deliberately started low for this reason — the starting dose is not a treatment dose.

The Ones That Need Attention

Severe persistent abdominal pain radiating to the back needs same-day assessment for pancreatitis. Gallstones are more common with rapid weight loss. In patients on insulin or sulfonylureas, those doses usually need reducing to avoid hypoglycaemia.

Protecting Muscle

A quarter or more of the weight lost can be lean mass if nothing is done about it. Every patient on these medicines should be on adequate protein — roughly 1.2 to 1.6 g per kg of ideal body weight — with resistance training twice a week. This is the single most neglected part of treatment, and it is what preserves metabolic rate.

What Happens If You Stop

Obesity behaves like hypertension: treat it and the numbers improve, stop and they drift back. Trials in which the medication was withdrawn showed roughly two-thirds of the lost weight returning within a year. That is not a flaw in the drug — it is the biology it was suppressing reasserting itself.

So the conversation at the start should be about years, not weeks. Some patients maintain on a reduced dose, some stop successfully after consolidating habits and muscle mass, and some need to continue. What does not work is stopping abruptly with no plan. Our obesity and weight management service builds that plan alongside the prescription.

When to See an Endocrinologist

Book a review if your BMI is 27 or above with a weight-related condition, if diet and exercise have plateaued, if you have type 2 diabetes alongside obesity, or if you are already on one of these medicines and are unsure about dosing, side effects or how long to continue. Assessment covers thyroid function, sugars, liver, lipids and other causes of weight gain before anything is prescribed.

Conclusion

Incretin therapy has moved obesity from a willpower conversation to a medical one, with results that were previously only possible after surgery. It works because it changes the signals that drive hunger, not because it forces discipline.

It still needs the basics around it — protein, resistance training, monitoring and a maintenance plan. Used that way, under supervision, it is the most effective medical weight treatment available today.

FAQs